Efficacy and safety of patent foramen ovale closure in patients with a cryptogenic stroke: Systematic review and meta-analysis

Francesco Dentali; Monica Gianni; Nicola Mumoli; Marco Cei; Andrea Bertolini; Luigina Guasti; Walter Ageno

doi:10.1160/TH13-06-0504

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 111(04): 773-776
DOI: 10.1160/TH13-06-0504

Letters to the Editor

Schattauer GmbH

Efficacy and safety of patent foramen ovale closure in patients with a cryptogenic stroke: Systematic review and meta-analysis

Authors

Francesco Dentali

¹Department of Clinical Medicine, Insubria University, Varese, Italy
Monica Gianni

²Department of Cardiology, Tradate Hospital, Tradate, Italy
Nicola Mumoli

²Department of Cardiology, Tradate Hospital, Tradate, Italy
Marco Cei

³Department of Internal Medicine, Ospedale Civile Livorno, Livorno, Italy
Andrea Bertolini

¹Department of Clinical Medicine, Insubria University, Varese, Italy
Luigina Guasti

¹Department of Clinical Medicine, Insubria University, Varese, Italy
Walter Ageno

¹Department of Clinical Medicine, Insubria University, Varese, Italy

Abstract

Full Text

References

References
1 Putaala J, Metso AJ, Metso TM. et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischaemic stroke: the Helsinki young stroke registry.. Stroke 2009; 40: 1195-1203.
2 Sacco RL, Ellenberg JH, Mohr JP. et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank.. Ann Neurol 1989; 25: 382-390.
3 Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies.. Neurology 2000; 55: 1172-1179.
4 Homma S, Sacco RL. Patent foramen ovale and stroke.. Circulation 2005; 112: 1063-1072.
5 Agarwal S, Bajaj NS, Kumbhani DJ. et al. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism.. JACC Cardiovasc Interv 2012; 5: 777-789.
6 Wahl A, Jüni P, Mono ML. et al. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.. Circulation 2012; 125: 803-812.
7 Furlan AJ, Reisman M, Massaro J. et al. CLOSURE I Investigators.. Closure or medical therapy for cryptogenic stroke with patent foramen ovale.. N Engl J Med 2012; 366: 991-999.
8 Carroll JD, Saver JL, Thaler DE. et al. RESPECT Investigators.. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.. N Engl J Med 2013; 368: 1092-1100.
9 Meier B, Kalesan B, Mattle HP. et al PC Trial Investigators.. Percutaneous closure of patent foramen ovale in cryptogenic embolism.. N Engl J Med 2013; 368: 1083-1091.
10 O’Gara PT, Messe SR, Tuzcu EM. et al. American Heart Association; American Stroke Association; American College of Cardiology Foundation.. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation.. Circulation 2009; 119: 2743-2747.
11 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1-12.
12 Cotter PE, Martin PJ, Ring L. et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke.. Neurology 2013; 80: 1546-1550.